Candel Therapeutics, Inc.CADLNASDAQ
LOADING
|||
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Gross Profit Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EBITDA Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Net Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Diluted Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Weighted Average Shares Growth | +10.70% | +22.72% | +8.49% | +72.33% | +71.47% |
| Weighted Average Shares Diluted Growth | +10.70% | +22.72% | +8.49% | +72.33% | +71.47% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Free Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Receivables Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Inventory Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Asset Growth | -57.02% | +156.26% | +207.22% | +300.11% | +335.00% |
| Book Value per Share Growth | +0.00% | +324.08% | +1051.26% | +0.00% | +0.00% |
| Debt Growth | -27.21% | -40.82% | -48.24% | -56.33% | -62.39% |
| R&D Expense Growth | -7.34% | -34.18% | +4.28% | +40.41% | +52.62% |
| SG&A Expenses Growth | +10.60% | +8.63% | +8.26% | +12.41% | +36.18% |